The court found 2 patent claims valid and infringed over Yutrepia, putting its U.S. availability at risk. Four other claims were invalidated, and Liquidia plans an appeal and label change, but possible market limits remain.
This puts Yutrepia’s ability to reach patients at risk. Four other patent claims were invalidated, and Liquidia plans to appeal and seek a label change. Still, the court found two claims valid and infringed, and the final remedy could limit access to the product.
The court upheld 2 United Therapeutics patent claims and found Liquidia infringed them over Yutrepia. Four other claims were invalidated, and remedies remain undecided, but the ruling strengthens United Therapeutics’ case against a rival product.
Follow Liquidia Corp (LQDA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LQDA